Despite these efforts, the only currently approved clinically actionable biomarkers or companion diagnostics (CDx) predicting responses to ICI therapies are still limited to PD-L1 immunohistochemistry, tumor mutational burden (TMB), and microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) tumor profiling [25–28]. Here, CD274 is linked to neoplasm.